LMAT (LeMaitre Vascular) Cyclically Adjusted Revenue per Share: $0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LMAT LeMaitre Vascular Inc LMAT
100 GF Score
Price $81.45
GF Value $95.26
Valuation Modestly Undervalued
View Full Analysis

What is LeMaitre Vascular Cyclically Adjusted Revenue per Share?

LeMaitre Vascular LMAT +0.78% 100 Cyclically Adjusted Revenue per Share is $0.00 as of Jun. 2026. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

LeMaitre Vascular's adjusted revenue per share for the three months ended in Jun. 2026 was $2.869. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, LeMaitre Vascular's average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of LeMaitre Vascular was 10.80% per year. The lowest was 1.40% per year. And the median was 7.40% per year.

As of today (2026-08-07), LeMaitre Vascular's current stock price is $81.45. LeMaitre Vascular's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $0.00. LeMaitre Vascular's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of LeMaitre Vascular was 14.73. The lowest was 4.45. And the median was 8.13.


LeMaitre Vascular  (NAS:LMAT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of LeMaitre Vascular was 14.73. The lowest was 4.45. And the median was 8.13.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


LeMaitre Vascular Cyclically Adjusted Revenue per Share Related Terms


LeMaitre Vascular Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for LeMaitre Vascular's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LeMaitre Vascular Cyclically Adjusted Revenue per Share Chart

LeMaitre Vascular Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.66 6.29 6.83 7.44 8.13

LeMaitre Vascular Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.85 8.02 8.13 8.42 0.00

LMAT vs PLSE, XRAY, ATRC: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LeMaitre Vascular Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where LeMaitre Vascular's Cyclically Adjusted PS Ratio falls into.


LMAT
100GF Score
LeMaitre Vascular Inc LMAT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LeMaitre Vascular Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, LeMaitre Vascular's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.869/333.9520*333.9520
=2.869

Current CPI (Jun. 2026) = 333.9520.

LeMaitre Vascular Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.206 241.428 1.668
201612 1.185 241.432 1.639
201703 1.225 243.801 1.678
201706 1.289 244.955 1.757
201709 1.232 246.819 1.667
201712 1.293 246.524 1.752
201803 1.288 249.554 1.724
201806 1.334 251.989 1.768
201809 1.191 252.439 1.576
201812 1.406 251.233 1.869
201903 1.410 254.202 1.852
201906 1.456 256.143 1.898
201909 1.428 256.759 1.857
201912 1.474 256.974 1.916
202003 1.495 258.115 1.934
202006 1.218 257.797 1.578
202009 1.779 260.280 2.283
202012 1.821 260.474 2.335
202103 1.721 264.877 2.170
202106 1.940 271.696 2.385
202109 1.749 274.310 2.129
202112 1.784 278.802 2.137
202203 1.790 287.504 2.079
202206 1.903 296.311 2.145
202209 1.757 296.808 1.977
202212 1.842 296.797 2.073
202303 2.113 301.836 2.338
202306 2.232 305.109 2.443
202309 2.109 307.789 2.288
202312 2.177 306.746 2.370
202403 2.369 312.332 2.533
202406 2.458 314.175 2.613
202409 2.401 315.301 2.543
202412 2.428 315.605 2.569
202503 2.615 319.799 2.731
202506 2.806 322.561 2.905
202509 2.503 324.800 2.574
202512 2.806 324.054 2.892
202603 2.890 330.213 2.923
202606 2.869 333.952 2.869

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
LeMaitre Vascular (LMAT) has a Cyclically Adjusted Revenue per Share of $0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on LeMaitre Vascular and its competitors.
Is LeMaitre Vascular's Cyclically Adjusted Revenue per Share too high?
LeMaitre Vascular's current Cyclically Adjusted Revenue per Share is $0.00. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Cyclically Adjusted Revenue per Share compare to PLSE and XRAY?
LeMaitre Vascular's Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on LeMaitre Vascular and its competitors. LeMaitre Vascular's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.00. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current Cyclically Adjusted Revenue per Share is $0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LeMaitre Vascular (LMAT) Overvalued in 2026?

Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued. The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26. GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.

Key valuation signals for LMAT:

  • Cyclically Adjusted Revenue per Share: $0.00
  • GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
  • GF Score™: 100/100

No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


LeMaitre Vascular Business Description

Other Exchanges LHU:Germany
Address 63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score

Get the complete analysis for LMAT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.45
Price
$95.26
GF Value